Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2014) 124 (21): 2142.

https://doi.org/10.1182/blood.V124.21.2142.2142

Published: 2014

Journal Articles

Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma

Salomon Manier, MD, Herve Avet-Loiseau, Federico Campigotto, MS, Siobhan Glavey, MD, Karma Salem, MD, Daisy Huynh, MPS, Erica N Boswell, BS, Antonio Sacco, BS, Yuji Mishima, PhD, Michele Moschetta, MD, Michaela R. Reagan, PhD, Yawara Kawano, MDPhD, Kenneth C. Anderson, MD, Aldo M Roccaro, MD PhD, Philippe Moreau, MD, Thierry Facon, MD, Xavier Leleu, MD PhD, Edie A. Weller, PhD, Irene M. Ghobrial, MD

Blood (2014) 124 (21): 2056.

https://doi.org/10.1182/blood.V124.21.2056.2056

Published: 2014

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients

Salomon Manier, MD, Erica N Boswell, BS, Siobhan Glavey, MD, Antonio Sacco, BS, Patricia Maiso, PhD, Yuji Mishima, PhD, Yosra Aljaway, BS, Ranjit Banwait, MA, Wenjing Zhang, MD, Yu Zhang, MD, Ilyas Sahin, MD, Michele Moschetta, MD, Yong Zhang, PhD, Michaela R Reagan, PhD, John M. Asara, PhD, Xavier Leleu, MD, PhD, Aldo M Roccaro, MD, PhD, Irene M. Ghobrial, MD

Blood (2013) 122 (21): 3086.

https://doi.org/10.1182/blood.V122.21.3086.3086

Published: 2013

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth Shain, MD, PhD, Courtney Hanlon, Ranjit Banwait, Abdel Kareem Azab, Bpharm, PhD, Jacob P. Laubach, MD, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Stacey Chuma, BSN, Erica N Boswell, BS, Patrick Mostyn, Leblebjian Houry, PharmD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1947.

https://doi.org/10.1182/blood.V122.21.1947.1947

Published: 2013

Journal Articles

Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Noopur Raje, MD, Philippe Armand, MD, PhD, Robert L. Schlossman, MD, Erica N Boswell, BS, Courtney Hanlon, Stacey Chuma, BSN, Damian R Handisides, Stewart Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1948.

https://doi.org/10.1182/blood.V122.21.1948.1948

Published: 2013

Journal Articles

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Patrick Mostyn, Farzana Masood, Paul G. Richardson, MD, Steven Peter Treon, MD, MA, PhD, Jeffrey Matous, MD

Blood (2013) 122 (21): 4402.

https://doi.org/10.1182/blood.V122.21.4402.4402

Published: 2013

Journal Articles

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N. Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous

Blood (2013) 121 (8): 1296–1303.

https://doi.org/10.1182/blood-2012-06-439307

Published: 2013

Journal Articles

Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients

Salomon Manier, MD, Erica N Boswell, BS, Antonio Sacco, BS, Patricia Maiso, PhD, Ranjit Banwait, MA, Yosra Aljawai, BS, Xavier Leleu, MD, PhD, Aldo M Roccaro, MD, PhD, Irene M. Ghobrial, MD

Blood (2012) 120 (21): 3975.

https://doi.org/10.1182/blood.V120.21.3975.3975

Published: 2012

Journal Articles

LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia

Blood (2011) 118 (21): 2728.

https://doi.org/10.1182/blood.V118.21.2728.2728

Published: 2011

Journal Articles

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Tiffany Poon, BS, Federico Campigotto, MS, Erica N Boswell, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Amanda Donovan, BS, Meghan Bagshaw, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Edie Weller, PhD, Timothy J. Murphy, MD, FACP, Jeffrey Matous, MD

Blood (2011) 118 (21): 2706.

https://doi.org/10.1182/blood.V118.21.2706.2706

Published: 2011

Journal Articles

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Ranjit Banwait, MA, Tiffany Poon, BS, Amanda Donovan, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Meghan Bagshaw, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 2705.

https://doi.org/10.1182/blood.V118.21.2705.2705

Published: 2011

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients

LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only